GSK agreed to acquire global rights to two siRNA candidates from Frontier Biotechnologies with a deal that starts with a $40 million upfront payment and could total nearly $1 billion in milestones. One candidate is already in Phase 1 in China; GSK will take responsibility for global development, regulatory filings, and commercialization. The agreement reflects the continued strategic push by large pharmas to add oligonucleotide modalities—particularly siRNA—to their pipelines. GSK cited the fit with its existing oligonucleotide and antiviral expertise and signaled plans to accelerate global development where appropriate. For the oligo ecosystem, the deal reinforces investor confidence and cross‑border sourcing of late‑stage biotech assets, while highlighting regulatory and clinical transfer challenges when advancing China‑originated molecules to global markets.